Literature DB >> 21997184

[Home care treatment of cancer pain patients with patient-controlled analgesia (PCA)].

E A Lux1, J Heine.   

Abstract

BACKGROUND: Only limited data and experience with patient-controlled analgesia (PCA) in outpatients for palliative home care, related to organization, effectiveness and costs are available. PATIENTS AND METHODS: In our retrospective study we analyzed the effectiveness, care intensity and pain reduction of 108 palliative cancer pain patients with PCA, included in a palliative home care system.
RESULTS: After equivalent conversion of the opioid doses from oral/transcutaneus to parenteral administration a dose increase was necessary in 12.9% of the patients. The pain therapy was effective until death for an average of 38.9 days (median 21 days). During 3,889 days of PCA therapy there were 76 unscheduled visits based on technical problems.
CONCLUSION: In cases of cancer pain patients with failed oral or transcutaneous opioid medication, sufficient pain reduction can be achieved with parenteral drug administration by PCA. Domestic PCA requires a lot of human and financial resources, with trained nursing services and regular house visits by physicians experienced in palliative medicine but this method is sufficient and safe to use.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997184     DOI: 10.1007/s00482-011-1101-9

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  6 in total

1.  Patient-controlled analgesia (PCA) in the domiciliary care of tumour patients.

Authors:  G Meuret; H Jocham
Journal:  Cancer Treat Rev       Date:  1996-01       Impact factor: 12.111

2.  Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: a report of 117 patients.

Authors:  G Swanson; J Smith; R Bulich; P New; R Shiffman
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

3.  [Patient-controlled analgesia (PCA) in outpatients with cancer pain. Analysis of 1,692 treatment days].

Authors:  C Schiessl; J Bidmon; R Sittl; N Griessinger; J Schüttler
Journal:  Schmerz       Date:  2007-02       Impact factor: 1.107

4.  [Outpatient opiate therapy in cancer patients during their last days of life].

Authors:  R Maier; A Maier; C Müller-Busch
Journal:  Schmerz       Date:  2008-04       Impact factor: 1.107

5.  Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.

Authors:  Sharon M Weinstein; John Messina; Fang Xie
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

6.  [Treatment of postoperative pain with intravenous PCA system. Comparison with morphine, metamizole, and buprenorphine].

Authors:  L M Torres; F Collado; J M Almarcha; V G Huertas; P de Antonio; M Rodríguez
Journal:  Rev Esp Anestesiol Reanim       Date:  1993 Jul-Aug
  6 in total
  3 in total

1.  Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review.

Authors:  Lisa Nijland; Pia Schmidt; Michael Frosch; Julia Wager; Bettina Hübner-Möhler; Ross Drake; Boris Zernikow
Journal:  Support Care Cancer       Date:  2018-07-28       Impact factor: 3.603

2.  Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.

Authors:  Angela Maria Sousa; José de Santana Neto; Gabriel M N Guimaraes; Giovana M Cascudo; José Osvaldo B Neto; Hazem A Ashmawi
Journal:  Support Care Cancer       Date:  2013-11-21       Impact factor: 3.603

3.  Patient-controlled subcutaneous analgesia using sufentainil or morphine in home care treatment in patients with stage III-IV cancer: A multi-center randomized controlled clinical trial.

Authors:  Cheng-Fu Wan; Qing-Zhu Meng; Yan-Wei Wang; Liang Qi; Chang-Liang Ai; Xin Sui; Tao Song
Journal:  Cancer Med       Date:  2020-06-04       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.